

Sunday, 19 April 12:00 CET Poster Area			
05a. Drug discovery and new compounds mechanisms of action & spectrum, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)			
Antabio	P2618	B / 2 / 29	Potent activity of the novel combination meropenem-ANT3310 against global <i>Acinetobacter baumannii</i> clinical isolates from 2019 to 2023
Debiopharm	P2637	B / 3 / 8	Afabicin desphosphono <i>in vitro</i> activity against <i>Staphylococcus</i> spp.: data from a five-year susceptibility surveillance study (2018-2023)
Monday, 20 April 11:00 CET			
Arena 3 Oral Presentation: MDR pathogens around the globe: mechanisms, risk, and treatment optimisation			
Shionogi	E0656		Activity of cefiderocol against <i>Stenotrophomonas maltophilia</i> clinical isolates collected in multi-national antimicrobial surveillance studies SIDERO-WT (2014 - 2019) and SENTRY (2020 - 2024)
Monday, 20 April 12:00 CET			
Poster Area 03a. Resistance surveillance & epidemiology: Community-acquired bacteria			
Pfizer	P1187	A / 1 / 12	<i>In vitro</i> activity of ceftazidime/avibactam and comparators against <i>Pseudomonas aeruginosa</i> in European countries: ATLAS global surveillance program: 2020-2024
Pfizer	P1188	A / 1 / 13	The <i>in vitro</i> activity of aztreonam/avibactam and comparator agents against epidemiological clones of carbapenem-resistant <i>Klebsiella pneumoniae</i> collected as a part of the ATLAS global surveillance program, 2024
Pfizer	P1189	A / 1 / 14	The <i>in vitro</i> activity of aztreonam/avibactam and comparator agents against isolates of hypervirulent <i>Klebsiella pneumoniae</i> with carbapenemases and ESBLs collected as a part of the ATLAS global surveillance program, 2024
Pfizer	P1195	A / 1 / 20	<i>In vitro</i> activity of ceftazidime/avibactam and comparators against Enterobacterales isolates encoding β -lactamases collected from paediatric patients as a part of the ATLAS global surveillance program, 2020-2024
Pfizer	P1196	A / 1 / 21	<i>In vitro</i> activity of ceftazidime/avibactam and comparators against <i>Pseudomonas aeruginosa</i> collected in Europe and Latin America, by β -lactamase carriage, ATLAS 2020-2024
Meiji	P1197	A / 1 / 22	Activity of the novel combination therapy cefepime/nacubactam against 17,220 clinical isolates of Enterobacterales collected worldwide during 2021-2024
Pfizer	P1207	A / 1 / 32	Changes in the <i>in vitro</i> activity of oral agents against isolates of community-acquired pathogens from respiratory infections in patients 18-64 years old, 2018-2024, collected as a part of the ATLAS global surveillance program
Monday, 20 April 12:00 CET			
Poster Area 03b. Resistance surveillance & epidemiology: Healthcare-associated bacteria			
Innoviva	P1324	A / 4 / 29	<i>In vitro</i> activity of sulbactam-durlobactam against global clinical <i>Acinetobacter baumannii-calcoaceticus</i> complex isolates collected in 2024
Merck	P1344	A / 5 / 9	<i>In vitro</i> activity of imipenem/relebactam against Enterobacterales and <i>Pseudomonas aeruginosa</i> collected in Taiwan: SMART 2020-2024
Merck	P1345	A / 5 / 10	Susceptibility of Gram-negative bacilli to ceftolozane/tazobactam and comparators collected in the Middle East from patients with bloodstream and respiratory tract infections in 2016-2020 compared to 2021-2024: study for monitoring antimicrobial resistance trends (SMART)
Merck	P1346	A / 5 / 11	Imipenem/relebactam activity against Gram-negative pathogens collected in South Africa: SMART 2020-2024

Merck	P1347	A / 5 / 12	<i>In vitro</i> activity of ceftolozane/tazobactam and comparators against <i>Pseudomonas aeruginosa</i> isolates from paediatric patients in Europe: SMART 2021-2024
Merck	P1348	A / 5 / 13	Activity of ceftolozane/tazobactam, imipenem/relebactam and comparators against clinical Gram-negative isolates collected from patients with respiratory tract infections in the Americas: SMART 2021-2024
Pfizer	P1352	A / 5 / 17	Changes in the <i>in vitro</i> activity of intravenous antimicrobial agents against hospital-acquired Gram-negative bacilli causing respiratory infections in patients 18-64 years old, collected as a part of the ATLAS global surveillance program 2018-2024
Antabio	P1373	A / 5 / 38	Potent activity of the novel combination Meropenem-ANT3310 against global OXA- and KPC-carbapenem-resistant Enterobacterales (CRE) clinical isolates from 2019 to 2023
Evopoint	P1466	A / 8 / 11	<i>In vitro</i> activity of funobactam (XNW4107) in combination with imipenem against Gram-negative isolates collected in 2022
Monday, 20 April 12:00 CET			
Poster Area 03d. Resistance mechanisms (incl <i>in vitro</i> and <i>in vivo</i> studies, mobile elements, excl TB)			
Pfizer	P1612	A / 11 / 37	Molecular characteristics of <i>Escherichia coli</i> ST131 isolates and <i>in vitro</i> activity of ceftazidime/avibactam against these isolates, by source and region, collected in 2024 as a part of the ATLAS global surveillance program
Pfizer	P1617	A / 12 / 2	The <i>in vitro</i> activity of ceftazidime/avibactam against the predominant epidemiological clones of carbapenem-resistant <i>Pseudomonas aeruginosa</i> , ATLAS 2024
Meiji	P1622 Top-Rated	A / 12 / 7	The <i>in vitro</i> activity of aztreonam/nacubactam and cefepime/nacubactam against molecularly characterised Enterobacterales isolates including those with ceftazidime-avibactam and aztreonam/avibactam resistance mechanisms collected globally from 2021-2023
Merck	P1647	A / 12 / 32	Inserts in penicillin-binding protein 3 among Enterobacterales isolates that carry AmpC and/or carbapenemases collected globally as a part of the SMART program, 2023
Pfizer	P1651	A / 12 / 36	Trends in the epidemiology of metallo- β -lactamases and extended-spectrum β -lactamases among clinical isolates of Enterobacterales, by region ATLAS 2019-2024
Pfizer	P1652	A / 12 / 37	The <i>in vitro</i> activity of aztreonam/avibactam and cefiderocol against <i>Escherichia coli</i> isolates that carry insertions in penicillin-binding protein 3 (PBP3) with and without acquired AmpC as a part of the ATLAS global surveillance program, 2024
Pfizer	P1653	A / 12 / 38	The <i>in vitro</i> activity of ceftazidime/avibactam and comparators against Enterobacterales isolates collected in Europe and Latin America, by β -lactamase carriage, ATLAS 2020-2024

Your Global Antimicrobial Partner

IHMA delivers comprehensive bacteriology and clinical microbiology services:

- Pre-clinical studies for regulatory filings
 - Global laboratory services for all phases of clinical trials including safety studies
- Antimicrobial resistance (AMR) surveillance (bacterial)
- Molecular characterization and detection of infectious agents
 - New therapeutic approaches (bacteriophage, vaccine, microbiome modulation, etc.)
- *in vitro* diagnostic device studies